CliffBio
small molecule

DAPTOMYCIN

DAPTOMYCIN

Loss of exclusivitySeptember 2033latest FDA-listed patent expiry
CompanyHospira →View the full company profile on CliffBio

Drug detail

Brand nameDAPTOMYCIN
Active ingredientDAPTOMYCIN
Strength500MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusRX

Listed patents

PatentExpiresType
10357535September 2033product
9655946September 2033product

More from Hospira

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAPTOMYCIN patent cliff — loss of exclusivity September 2033 | CliffBio